Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456782 | 0.75 | — | — | |
| SCHEMBL7617975 | 0.75 | MPO (0.36) | MPO | |
| SCHEMBL7487796 | 0.71 | MPO (0.36) | MPO | |
| SCHEMBL122460 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL4076427 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL6904577 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL308136 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL9634551 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL4934278 | 0.62 | — | — | |
| SCHEMBL3143238 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117461704-A | Instant lossless tea and preparation method thereof | 昆明裕莱生物科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-9211336-B2 | Antioxidant stabilized pharmaceutical formulations comprising antineoplastic compounds | HIKMA PHARMACEUTICALS (JO) | 2015-12-15 | — | — | US | disclosed |
| US-9211335-B2 | Stabilized pharmaceutical formulations comprising antineoplastic compounds | HIKMA PHARMACEUTICALS (JO) | 2015-12-15 | — | — | US | disclosed |
| US-20150148391-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | HIKMA PHARMACEUTICALS (JO) | 2015-05-28 | — | — | US | disclosed |
| US-8974811-B2 | Stabilized pharmaceutical formulations comprising antineoplastic compounds | HIKMA PHARMACEUTICALS (JO) | 2015-03-10 | — | — | US | disclosed |
| US-20140309197-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | HIKMA PHARMACEUTICALS (JO) | 2014-10-16 | — | — | US | disclosed |
| US-20140275195-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | HIKMA PHARMACEUTICALS (JO) | 2014-09-18 | — | — | US | disclosed |
| EP-2777702-A1 | Stabilized pharmaceutical formulations comprising antineoplastic compounds | Hikma Pharmaceuticals (JO) | 2014-09-17 | — | — | EP | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309197-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TXNRD2, NQO1 | MPO 110/4885 |
| US-20150148391-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TXNRD2, NQO1 | MPO 110/4885 |
| US-20140275195-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS COMPRISING ANTINEOPLASTIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TXNRD2, NQO1 | MPO 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.